Sionna Therapeutics (NASDAQ:SION) Cut to Hold at JonesTrading

Sionna Therapeutics (NASDAQ:SION) was downgraded by investment analysts at JonesTrading from a “strong-buy” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on the stock. Guggenheim cut shares of Sionna Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday. Wedbush downgraded Sionna Therapeutics from an “outperform” rating to a “neutral” rating and set a $5.00 target price on the stock. in a report on Monday. Stifel Nicolaus reissued a “hold” rating and issued a $7.00 target price on shares of Sionna Therapeutics in a research note on Monday. BTIG Research lowered Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Wednesday, August 5th. One analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Sionna Therapeutics has an average rating of “Hold” and an average price target of $42.22.

Sionna Therapeutics Stock Performance

SION opened at $5.10 on Monday. The stock has a market capitalization of $230.58 million, a PE ratio of -2.34 and a beta of 1.32. The stock’s 50 day moving average price is $40.99 and its 200-day moving average price is $39.92. Sionna Therapeutics has a 52-week low of $4.01 and a 52-week high of $54.97.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). Research analysts forecast that Sionna Therapeutics will post -2.66 EPS for the current fiscal year.

Insider Buying and Selling at Sionna Therapeutics

In other news, Director Orbimed Advisors Llc sold 85,918 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the transaction, the director directly owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the sale, the director directly owned 2,469,959 shares in the company, valued at $110,802,360.74. This trade represents a 3.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 403,726 shares of company stock worth $18,259,354. Company insiders own 5.10% of the company’s stock.

Institutional Trading of Sionna Therapeutics

A number of large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. bought a new stake in shares of Sionna Therapeutics in the third quarter worth approximately $30,000. BNP Paribas Financial Markets bought a new position in Sionna Therapeutics during the second quarter valued at approximately $31,000. State of Wyoming purchased a new stake in Sionna Therapeutics in the second quarter worth approximately $35,000. GF Fund Management CO. LTD. purchased a new stake in Sionna Therapeutics in the fourth quarter worth approximately $36,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Sionna Therapeutics in the 2nd quarter worth approximately $44,000.

Key Sionna Therapeutics News

Here are the key news stories impacting Sionna Therapeutics this week:

• Negative Sentiment: SION-719 failed its Phase 2 primary endpoint. The experimental cystic-fibrosis treatment did not produce the expected improvement, prompting Sionna to discontinue development of SION-719 as an add-on therapy. The failure eliminates the company’s principal near-term clinical catalyst and raises uncertainty about the value of its broader pipeline. Sionna Therapeutics Halts Lead Cystic Fibrosis Drug After Phase 2 Failure
• Negative Sentiment: The stock dropped roughly 90% to a record low. The magnitude of the decline reflects investors’ reassessment of Sionna’s prospects following the unexpected trial miss and the loss of its lead drug program. Trading volume was also unusually heavy compared with the company’s average. Sionna Therapeutics stock falls 92% after SION-719 trial failure
• Negative Sentiment: Analysts cut their ratings after the clinical setback. BTIG and Guggenheim moved from “buy” to “neutral,” while Raymond James, Citizens JMP and Wedbush also reduced their ratings. Wedbush and RBC set approximately $5 price targets, signaling limited expected upside at current levels. Sionna Discontinues Cystic Fibrosis Drug Following Unfavorable Data
• Neutral Sentiment: Sionna reported mixed results from two cystic-fibrosis programs and plans to refocus its pipeline. However, the company has not yet identified a replacement asset with comparable clinical maturity, leaving its future strategy and financing needs uncertain. Sionna Reports Mixed Trial Results and Refocuses CF Pipeline
• Neutral Sentiment: The failure benefits rival Vertex Pharmaceuticals. Sionna’s unsuccessful trial removes a potential competitor to Vertex’s established cystic-fibrosis franchise, which explains why Vertex shares rose as Sionna’s stock declined. Vertex Shares Rise as Rival Sionna Trial Fails

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.